Get the Stockscreener App
26.94
3.02%
0.79
After Hours:
26.94
Acadia Pharmaceuticals Inc stock is traded at $26.94, with a volume of 1.37M.
It is up +3.02% in the last 24 hours and down -1.82% over the past month.
Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has two core franchises in neuroscience and neuro-rare diseases. The neuroscience franchise is anchored by its commercial product NUPLAZID (pimavanserin), which is used for the treatment of hallucinations and delusions associated with Parkinson's Disease Psychosis (PDP). The neuro-rare disease franchise is anchored by the commercial product DAYBUE, which is used for the treatment of Rett syndrome. In addition, the company has various product candidates under development in different stages, including ACP-204, ACP-101, ACP-211, ACP-711, ACP-2591, etc.
See More
Previous Close:
$26.15
Open:
$26.5
24h Volume:
1.37M
Relative Volume:
0.84
Market Cap:
$4.56B
Revenue:
$890.53M
Net Income/Loss:
$30.57M
P/E Ratio:
149.67
EPS:
0.18
Net Cash Flow:
$80.53M
1W Performance:
+0.90%
1M Performance:
-1.82%
6M Performance:
+28.59%
1Y Performance:
+54.30%
1-Day Range:
$26.36
$26.98
1-Week Range:
$25.56
$26.98
52-Week Range:
$13.40
$28.35
Acadia Pharmaceuticals Inc Stock (ACAD) Company Profile
Name
Acadia Pharmaceuticals Inc
Sector
Industry
Phone
858-558-2871
Address
12830 EL CAMINO REAL, SAN DIEGO
Compare ACAD with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ACAD
Acadia Pharmaceuticals Inc
|
26.94 | 4.42B | 890.53M | 30.57M | 80.53M | 0.18 |
|
VRTX
Vertex Pharmaceuticals Inc
|
468.38 | 113.87B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
776.54 | 80.22B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
406.40 | 52.56B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
803.74 | 49.31B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
175.07 | 37.37B | 447.02M | -1.18B | -906.14M | -6.1812 |
Acadia Pharmaceuticals Inc Stock (ACAD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-21-25 | Initiated | Citigroup | Buy |
| May-21-25 | Upgrade | Deutsche Bank | Hold → Buy |
| Feb-11-25 | Initiated | Deutsche Bank | Hold |
| Jan-03-25 | Downgrade | Guggenheim | Buy → Neutral |
| Oct-10-24 | Resumed | Raymond James | Mkt Perform |
| Aug-07-24 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jun-27-24 | Initiated | BMO Capital Markets | Outperform |
| Mar-12-24 | Downgrade | Mizuho | Buy → Neutral |
| Mar-12-24 | Reiterated | Needham | Buy |
| Jan-30-24 | Initiated | Robert W. Baird | Outperform |
| Jan-24-24 | Upgrade | Needham | Hold → Buy |
| Dec-19-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Dec-14-23 | Downgrade | Deutsche Bank | Buy → Hold |
| Dec-13-23 | Initiated | Citigroup | Buy |
| Dec-12-23 | Initiated | Deutsche Bank | Buy |
| Nov-06-23 | Upgrade | Mizuho | Neutral → Buy |
| Oct-17-23 | Initiated | UBS | Buy |
| Oct-10-23 | Upgrade | JP Morgan | Neutral → Overweight |
| Jan-03-23 | Upgrade | Guggenheim | Neutral → Buy |
| Nov-04-22 | Downgrade | Goldman | Neutral → Sell |
| Nov-01-22 | Initiated | Loop Capital | Hold |
| Aug-08-22 | Downgrade | Citigroup | Buy → Neutral |
| Aug-05-22 | Downgrade | Citigroup | Buy → Neutral |
| Jun-21-22 | Downgrade | Jefferies | Buy → Underperform |
| Jun-16-22 | Upgrade | Jefferies | Hold → Buy |
| Mar-16-22 | Upgrade | Canaccord Genuity | Hold → Buy |
| Feb-09-22 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Jan-05-22 | Upgrade | Citigroup | Neutral → Buy |
| Dec-21-21 | Downgrade | Guggenheim | Buy → Neutral |
| Nov-01-21 | Upgrade | Guggenheim | Neutral → Buy |
| Oct-14-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Sep-23-21 | Resumed | Needham | Hold |
| Jun-10-21 | Initiated | Berenberg | Hold |
| Apr-07-21 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Apr-06-21 | Downgrade | Canaccord Genuity | Buy → Hold |
| Apr-06-21 | Downgrade | Goldman | Buy → Neutral |
| Apr-06-21 | Downgrade | Jefferies | Buy → Hold |
| Apr-06-21 | Downgrade | Mizuho | Buy → Neutral |
| Apr-05-21 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Mar-10-21 | Downgrade | BofA Securities | Buy → Neutral |
| Mar-09-21 | Downgrade | Citigroup | Buy → Neutral |
| Mar-09-21 | Downgrade | Guggenheim | Buy → Neutral |
| Mar-09-21 | Reiterated | H.C. Wainwright | Buy |
| Mar-09-21 | Downgrade | Raymond James | Strong Buy → Outperform |
| Mar-09-21 | Downgrade | Stifel | Buy → Hold |
| Dec-16-20 | Initiated | Mizuho | Buy |
| Nov-16-20 | Upgrade | Raymond James | Outperform → Strong Buy |
| Aug-25-20 | Initiated | Raymond James | Outperform |
| Aug-20-20 | Initiated | Morgan Stanley | Overweight |
| Jul-07-20 | Upgrade | Stifel | Hold → Buy |
| Apr-16-20 | Initiated | Jefferies | Buy |
| Mar-31-20 | Upgrade | Goldman | Neutral → Buy |
| Mar-06-20 | Initiated | Citigroup | Buy |
| Dec-16-19 | Initiated | Guggenheim | Buy |
| Oct-24-19 | Initiated | Oppenheimer | Perform |
| Oct-01-19 | Initiated | RBC Capital Mkts | Outperform |
| Sep-13-19 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Sep-10-19 | Upgrade | Canaccord Genuity | Hold → Buy |
| Jul-23-19 | Reiterated | Needham | Buy |
| Dec-10-18 | Initiated | Canaccord Genuity | Hold |
| Sep-21-18 | Upgrade | Piper Jaffray | Neutral → Overweight |
| Aug-09-18 | Reiterated | Stifel | Hold |
| Aug-07-18 | Initiated | Stifel | Hold |
| Aug-06-18 | Downgrade | Piper Jaffray | Overweight → Neutral |
| Oct-06-17 | Resumed | Goldman | Neutral |
View All
Acadia Pharmaceuticals Inc Stock (ACAD) Latest News
ACADIA Pharmaceuticals (ACAD) Sees Target Price Raised by Citigr - GuruFocus
UBS Raises Price Target to $40 for ACADIA Pharmaceuticals (ACAD) - GuruFocus
ACADIA Pharmaceuticals (NASDAQ:ACAD) Cut to "Hold" at Wall Street Zen - MarketBeat
What drives ACADIA Pharmaceuticals Inc stock priceMean Reversion Trades & Outstanding Wealth Building - earlytimes.in
ACADIA Pharmaceuticals Earnings Notes - Trefis
Insider Sell: Is ACADIA Pharmaceuticals Inc stock in correction or buying zoneIndex Update & Risk Controlled Swing Alerts - moha.gov.vn
(ACAD) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
Deutsche Bank Upgrades ACADIA Pharmaceuticals (ACAD) - MSN
Performance Recap: Can ACADIA Pharmaceuticals Inc stock hit analyst price targetsWeekly Earnings Recap & Verified Swing Trading Watchlists - moha.gov.vn
Rice Hall James & Associates LLC Sells 54,869 Shares of ACADIA Pharmaceuticals Inc. $ACAD - MarketBeat
Acadia Stock Up 59% in a Year — Is a $51 Million New Stake a Bet on a Bigger Rebound? - AOL.com
Here's why Acadia Pharmaceuticals (ACAD) is a strong momentum stock - MSN
ACADIA Pharmaceuticals Advances Alzheimer’s Disease Psychosis Study with ACP-204 - MSN
Here's Why Acadia Pharmaceuticals (ACAD) is a Strong Momentum Stock - sharewise.com
Acadia Pharmaceuticals stock reaches 52-week high at $27.73 By Investing.com - Investing.com Nigeria
ACADIA Pharmaceuticals (NASDAQ:ACAD) Hits New 1-Year HighHere's Why - MarketBeat
Acadia Pharmaceuticals stock reaches 52-week high at $27.73 - Investing.com
Acadia Pharmaceuticals price target raised to $29 from $24 at Mizuho - MSN
Assessing ACADIA Pharmaceuticals (ACAD) Valuation After Its Strong 1-Year Share Price Rally - Yahoo Finance
Can ACADIA Pharmaceuticals Inc. stock maintain growth trajectoryWeekly Trading Summary & Reliable Breakout Stock Forecasts - Улправда
How ACADIA Pharmaceuticals Inc. stock compares to growth peers2025 EndofYear Setup & Weekly High Return Forecasts - ulpravda.ru
Market Recap: How ACADIA Pharmaceuticals Inc. stock compares to growth peersJuly 2025 Setups & Community Verified Trade Signals - Улправда
Is ACADIA Pharmaceuticals Inc. stock a defensive play in 2025Portfolio Update Summary & Fast Momentum Stock Entry Tips - Улправда
Can ACADIA Pharmaceuticals Inc. stock hit analyst price targets2025 Major Catalysts & Precise Buy Zone Identification - DonanımHaber
Will ACADIA Pharmaceuticals Inc. stock see PE expansionWeekly Trend Report & High Conviction Trade Alerts - DonanımHaber
Can ACADIA Pharmaceuticals Inc. stock attract ESG capital inflowsJuly 2025 Patterns & Real-Time Buy Signal Alerts - DonanımHaber
Acadia Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 13, 2026 - Yahoo Finance
Is ACADIA Pharmaceuticals Inc. stock a good choice for value investorsQuarterly Portfolio Summary & Safe Capital Growth Trade Ideas - Улправда
What is HC Wainwright's Forecast for ACAD FY2028 Earnings? - MarketBeat
FDA approves Acadia’s Daybue Stix for Rett syndrome - MSN
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat
Stifel maintains ACADIA Pharmaceuticals (ACAD) hold recommendation - MSN
New DAYBUE STIX Rett Syndrome Formulation Might Change The Case For Investing In ACADIA Pharmaceuticals (ACAD) - simplywall.st
Acadia Pharmaceuticals stock price target raised to $37 by H.C. Wainwright - Investing.com
ACADIA Pharmaceuticals Inc. $ACAD Stock Position Trimmed by Hudson Bay Capital Management LP - MarketBeat
Neuren partner Acadia bags FDA go-ahead for new DAYBUE STIX powder for Rett Syndrome - Indian Pharma Post
ACAD Sees Boost in Price Target by HC Wainwright & Co. | ACAD St - GuruFocus
Neuren Pharmaceuticals’ partner Acadia gains FDA approval for new Rett syndrome treatment - MSN
FDA Approves Acadia Pharmaceuticals’ Daybue Stix for Treating Rett Syndrome - geneonline.com
FDA approves Acadia’s Daybue Stix for Rett syndrome treatment - Pharmaceutical Technology
Neuren Pharmaceuticals’ Partner Acadia Gains FDA Approval for New Rett Syndrome Treatment - TipRanks
Hohimer Wealth Management LLC Decreases Position in ACADIA Pharmaceuticals Inc. $ACAD - MarketBeat
TFG Asset Management GP Ltd Has $3.48 Million Stake in ACADIA Pharmaceuticals Inc. $ACAD - MarketBeat
Eventide Asset Management LLC Trims Holdings in ACADIA Pharmaceuticals Inc. $ACAD - MarketBeat
Birchview Capital LP Sells 75,600 Shares of ACADIA Pharmaceuticals Inc. $ACAD - MarketBeat
FDA approves powder formulation of trofinetide for Rett syndrome - Contemporary Pediatrics
Acadia Pharmaceuticals Announces FDA Approval of DAYBUE® STIX (t - GuruFocus
FDA Approves New Formulation for Acadia Pharmaceuticals' (ACAD) Rett Syndrome Treatment - GuruFocus
Acadia Pharmaceuticals Announces FDA Approval of DAYBUE® STIX (trofinetide) for Oral Solution, a New Powder Formulation of Trofinetide for the Treatment of Rett Syndrome - Eagle-Tribune
Acadia Pharmaceuticals Inc Stock (ACAD) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.52%
0.07%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):